A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
18 Years and older, Male and Female
KTX-MMSET-001 (primary)
NCI-2023-01697
EUCTR No: 2022-500801-41-00
Summary
A Phase I study to evaluate the safety of a novel, orally available, selective, and
potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also
known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with
relapsed or refractory multiple myeloma (RRMM).
Objectives
This is a Phase I, open-label, dose escalation and expansion study in adult patients with
RRMM.
In the dose escalation phase (Part A), patients will be evaluated for DLTs during Cycle 1
(28 days). The KTX-1001 MTD, RP2D, and schedule will be determined.
In the dose expansion phase (Part B), patients with translocation t(4;14) or a GOF
mutation in MMSET (eg, E1099K) will be enrolled. Patients will receive KTX-1001 at the
RP2D to further define safety and tolerability and provide preliminary efficacy
information.
Eligibility
- = 18 years of age
- ECOG score = 2
- Relapsed or refractory multiple myeloma (as per IMWG)
- = 3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 antibody
- Patients must have exhausted available therapeutic options that are expected to provide a meaningful clinical benefit, either through disease relapse, treatment refractory disease, intolerance, or refusal of the therapy
- t(4;14) confirmed by standard of care FISH testing, or GOF mutation in MMSET confirmed by local sequencing test (Part B dose expansion cohorts only)
- Measurable disease, including at least 1 of the following criteria:
- Serum M protein = 0.50 g/dL (by SPEP)
- Serum IgA = 0.50 g/dL (IgA myeloma patients)
- Urine M protein = 200 mg/24 h (by UPEP)
- sFLC involved light chain = 10 mg/dL (100 mg/L) (patients with abnormal sFLC ratio)
- = 1 extramedullary lesion = 1 cm in size and able to be followed by imaging assessments (Part A dose escalation cohorts only)
- Bone marrow plasma cells = 10% (Part A dose escalation cohorts only) Key
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.